Literature DB >> 31094214

Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Li-Shuang Zhang1, Jun-Hua Zhang1, Rui Feng1, Xin-Yao Jin1, Feng-Wen Yang1, Zhao-Chen Ji1, Meng-Yu Zhao1, Ming-Yan Zhang1, Bo-Li Zhang1, Xue-Mei Li2.   

Abstract

To systematically evaluate the efficacy and safety of berberine for the treatment of hyperlipidemia, six electronic literature databases including SinoMed, CNKI, WanFang Data, PubMed, Embase and The Cochrane Library were searched to collect clinical randomized controlled trials (RCTs) of berberine alone or combined with statins for the treatment of hyperlipidemia from the inception to 8 March 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included RCTs. Then, meta-analysis was performed by using RevMan 5.3 software. A total of 11 RCTs involving 1386 patients were finally included. The results of meta-analysis showed that compared with the placebo group, berberine could significantly reduce the total cholesterol and low-density lipoprotein levels and elevate the high density lipoprotein level ( P<0.05 ). Compared with the simvastatin group, berberine was effective only in reducing the level of triglyceride ( MD=-0.37 , 95% CI: - 0.66, - 0.07, P=0.02 ). There, however, was no statistical significance between the BBR group and simvastatin group in the low density lipoprotein and high density lipoprotein levels. Compared with the simvastatin group, berberine plus simvastatin was more effective in reducing the level of triglyceride ( MD=-0.33 , 95% CI: - 0.46, - 0.20, P<0.00001 ) and total cholesterol ( MD=-0.36 , 95% CI: - 0.60, - 0.12, P=0.003 ). In terms of adverse reactions, the incidence of adverse reactions including transaminase elevation and muscle aches was lower in the berberine alone or combined with simvastatin group than that in the control group, while the instance of constipation was higher. This study suggests that berberine is effective for hyperlipidemia. The quality and quantity of included studies, however, were dissatisfactory, which might decrease the reliability of the results. Higher quality studies are needed to provide more high quality evidence.

Entities:  

Keywords:  Berberine; Hyperlipidemia; Meta-Analysis; Statins; Systematic Review

Mesh:

Substances:

Year:  2019        PMID: 31094214     DOI: 10.1142/S0192415X19500393

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  6 in total

Review 1.  Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease.

Authors:  Anna Och; Marek Och; Renata Nowak; Dominika Podgórska; Rafał Podgórski
Journal:  Molecules       Date:  2022-02-17       Impact factor: 4.411

2.  The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile.

Authors:  Dorota Wultańska; Michał Piotrowski; Hanna Pituch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-03-05       Impact factor: 3.267

Review 3.  Beta-Blockers and Berberine: A Possible Dual Approach to Contrast Neuroblastoma Growth and Progression.

Authors:  Maura Calvani; Angela Subbiani; Gennaro Bruno; Claudio Favre
Journal:  Oxid Med Cell Longev       Date:  2020-08-12       Impact factor: 6.543

Review 4.  Promising Antioxidative Effect of Berberine in Cardiovascular Diseases.

Authors:  Na An; Guoxia Zhang; Yingjian Li; Chao Yuan; Fan Yang; Lijing Zhang; Yonghong Gao; Yanwei Xing
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

5.  Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Yuanlong Sun; Na Hu; Gaofeng Chen; Yanjie Wang; Yiyang Hu; Maojun Ge; Yu Zhao
Journal:  Trials       Date:  2022-02-02       Impact factor: 2.279

6.  Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study.

Authors:  Jie Ming; Xinwen Yu; Xiaoqiang Xu; Li Wang; Chao Ding; Zhifeng Wang; Xuan Xie; Sheli Li; Wenjuan Yang; Shu Luo; Qingzhen He; Yafang Du; Zhufang Tian; Xiling Gao; Kaiyan Ma; Yujie Fang; Chen Li; Jiajun Zhao; Xiaokai Wang; Qiuhe Ji
Journal:  Genome Med       Date:  2021-08-09       Impact factor: 11.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.